nach oben

Erschienen in:

01.05.2008 | Epidemiology

Active and passive smoking, IL6, ESR1, and breast cancer risk

verfasst von: Martha L. Slattery, Karen Curtin, Anna R. Giuliano, Carol Sweeney, Richard Baumgartner, Sandra Edwards, Roger K. Wolff, Kathy B. Baumgartner, Tim Byers

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

We evaluated the association between smoking and risk of breast cancer in non-Hispanic white (NHW) and Hispanic or American Indian (HAI) women living in the Southwestern United States. Data on lifetime exposure to active and passive smoke data were available from 1527 NHW cases and 1601 NHW controls; 798 HAI cases and 924 HAI controls. Interleukin 6 (IL6) and Estrogen Receptor alpha (ESR1) polymorphisms were assessed in conjunction with smoking. Pack-years of smoking (≥15) were associated with increased risk of pre-menopausal breast cancer among NHW women (OR 1.6, 95% CI 1.1–2. 4). Passive smoke increased risk of pre-menopausal breast cancer for HAI women (OR 1.9, 95% CI 1.1–3.1 everyone; OR 2.3, 95% CI 1.2–4.5 nonsmokers). HAI pre-menopausal women who were exposed to 10+ h of passive smoke per week and had the rs2069832 IL6 GG genotype had over a fourfold increased risk of breast cancer (OR 4.4, 95% CI 1.5–12.8; P for interaction 0.01). Those with the ESR1 Xba1 AA genotype had a threefold increased risk of breast cancer if they smoked ≥15 pack-years relative to non-smokers (P interaction 0.01). These data suggest that breast cancer risk is associated with active and passive smoking.

Cui Y, Miller AB, Rohan TE (2006) Cigarette smoking and breast cancer risk: update of a prospective cohort study. Breast Cancer Res Treat 100(3):293–299PubMedCrossRef

Morabia A (2002) Smoking (active and passive) and breast cancer: epidemiologic evidence up to June 2001. Environ Mol Mutagen 39(2–3):89–95PubMedCrossRef

Terry PD, Rohan TE (2002) Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 11(10 1):953–971PubMed

Petrakis NL, Maack CA, Lee RE, Lyon M (1980) Mutagenic activity in nipple aspirates of human breast fluid. Cancer Res 40(1):188–189PubMed

Lissowska J, Brinton LA, Zatonski W, Blair A, Bardin-Mikolajczak A, Peplonska B, Sherman ME, Szeszenia-Dabrowska N, Chanock S, Garcia-Closas M(2006) Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer 119(8):1961–1969PubMedCrossRef

Reynolds P, Hurley S, Goldberg DE, Anton-Culver H, Bernstein L, Deapen D, Horn-Ross PL, Peel D, Pinder R, Ross RK et al (2004) Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst 96(1):29–37PubMedCrossRef

IARC (International Agency for Research on Cancer) (1986) Biological data relevant to the evaluation of carcinogenic risk to humans in IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Tobacco Smoking, vol 38. IARC, Lyon, p 127

Terry PD, Goodman M (2006) Is the association between cigarette smoking and breast cancer modified by genotype? A review of epidemiologic studies and meta-analysis. Cancer Epidemiol Biomarkers Prev 15(4):602–611PubMedCrossRef

Morabia A, Lash TL (2002) Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 12(1):85–88PubMedCrossRef

10.

Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, Manson JE, Colditz GA, Willett WC, Speizer FE et al (1997) A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 18(11):2127–2132PubMedCrossRef

11.

Martin RCM, Ahn JP, Nowell SAP, Hein DWP, Doll MA, Martini BD, Ambrosone CBP (2006) Association between Manganese Superoxide Dismutase Promoter Gene Polymorphism and Breast Cancer Survival. Breast Cancer Res 8(4):R45PubMedCrossRef

12.

Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, Hunter DJ (2004) Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13(6):989–996PubMed

13.

Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM (2002) Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 89(9):1117–1119PubMedCrossRef

14.

Knupfer H, Preiss R (2006) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102(2):129–135PubMedCrossRef

15.

Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14(10):2413–2418PubMedCrossRef

16.

Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88(1):255–259PubMedCrossRef

17.

Slattery ML CK, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RK (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the Southwestern United States. Cancer Epidemiol Biomarkers Prev 16(4):747–755PubMedCrossRef

18.

Becherini L, Gennari L, Masi L, Mansani R, Massart F, Morelli A, Falchetti A, Gonnelli S, Fiorelli G, Tanini A et al (2000) Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet 9(13):2043–2050PubMedCrossRef

19.

van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink AP, Arp PP, Colin EM, Fang Y, Hofman A, van Duijn CM et al (2003) Association of 5’ estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet 12(14):1745–1754PubMedCrossRef

20.

Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) The Estrogen Receptor alpha Gene and Breast Cancer Risk (The Netherlands). Cancer Causes Control 16(10):1195–1202PubMedCrossRef

21.

Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA (2005) Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women. Int J Cancer 116(6):984–991PubMedCrossRef

22.

Boyapati SM, Shu XO, Ruan ZX, Cai Q, Smith JR, Wen W, Gao YT, Zheng W (2005) Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival. Clin Cancer Res 11(3):1093–1098PubMed

23.

Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R et al (2004) Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 64(24):8891–8900PubMedCrossRef

24.

Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207(2):139–146PubMedCrossRef

25.

Salamone LM, Glynn NW, Black DM, Ferrell RE, Palermo L, Epstein RS, Kuller LH, Cauley JA (1996) Determinants of premenopausal bone mineral density: the interplay of genetic and lifestyle factors. J Bone Miner Res 11(10):1557–1565PubMedCrossRef

26.

Howard CA, Samet JM, Buechley RW, Schrag SD, Key CR (1983) Survey research in New Mexico Hispanics: some methodological issues. Am J Epidemiol 117(1):27–34PubMed

27.

Word DL PR (1996) Building a Spanish surname list for the 1990s–A new approach to an old problem. In: US Bureau of the Census, Population Division Working Paper No 13

28.

Slattery ML, Sweeney C, Edwards S, Herrick J, Baumgartner K, Wolff R, Murtaugh M, Baumgartner R, Giuliano A, Byers T (2006) Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat 102:85–101CrossRef

29.

Slattery ML, Sweeney C, Edwards S, Herrick JS, Baumgartner KB, Wolff RK, Murtaugh MA, Baumgartner R, Giuliano A, Byers T (2006) Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat (in press)

30.

Ainsworth BE, Irwin ML, Addy CL, Whitt MC, Stolarczyk LM (1999) Moderate physical activity patterns of minority women: the Cross-Cultural Activity Participation Study. J Womens Health Gend Based Med 8(6):805–813PubMedCrossRef

31.

Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett DR Jr., Schmitz KH, Emplaincourt PO et al (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32(9 Suppl):S498–S504PubMed

32.

Slattery ML, Sweeney C, Herrick J, Wolff R, Baumgartner K, Giuliano A, Byers T (2006) ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States. Breast Cancer Res Treat

33.

Kropp S, Chang-Claude J (2002) Active and passive smoking and risk of breast cancer by age 50 years among German women. Am J Epidemiol 156(7):616–626PubMedCrossRef

34.

Russo J, Tay LK, Russo IH (1982) Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2(1):5–73PubMedCrossRef

35.

Russo J, Tay LK, Ciocca DR, Russo IH (1983) Molecular and cellular basis of the mammary gland susceptibility to carcinogenesis. Environ Health Perspect 49:185–199PubMedCrossRef

36.

Olson JE, Vachon CM, Vierkant RA, Sweeney C, Limburg PJ, Cerhan JR, Sellers TA (2005) Prepregnancy exposure to cigarette smoking and subsequent risk of postmenopausal breast cancer. Mayo Clin Proc 80(11):1423–1428PubMedCrossRef

37.

Egan KM, Stampfer MJ, Hunter D, Hankinson S, Rosner BA, Holmes M, Willett WC, Colditz GA (2002) Active and passive smoking in breast cancer: prospective results from the Nurses’ Health Study. Epidemiology 13(2):138–145PubMedCrossRef

38.

Band PR, Le ND, Fang R, Deschamps M (2002) Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360(9339):1044–1049PubMedCrossRef

39.

Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L (2001) Smoking associated with hormone receptor negative breast cancer. Int J Cancer 91(4):580–584PubMedCrossRef

40.

Li CI, Malone KE, Daling JR (2005) The relationship between various measures of cigarette smoking and risk of breast cancer among older women 65-79 years of age (United States). Cancer Causes Control 16(8):975–985PubMedCrossRef

41.

Windham GC, Mitchell P, Anderson M, Lasley BL (2005) Cigarette smoking and effects on hormone function in premenopausal women. Environ Health Perspect 113(10):1285–1290PubMedCrossRef

42.

van der Hel OL, Peeters PH, Hein DW, Doll MA, Grobbee DE, Kromhout D, Bueno de Mesquita HB (2003) NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13(7):399–407PubMedCrossRef

43.

Huang CS, Chern HD, Shen CY, Hsu SM, Chang KJ (1999) Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int J Cancer 82(2):175–179PubMedCrossRef

44.

Morabia A, Bernstein M, Heritier S (1998) Re: Hunter DJ, Hankinson SE, Hough H et al. (1997), A prospective study of NAT2 acetylation genotype, cigarette smoking and risk of breast cancer. Carcinogenesis, 18, 2127–2132. Carcinogenesis 19(9):1705

45.

Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES, Hassan MM, Li D (2002) Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 23(2):301–306PubMedCrossRef

46.

Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A (2002) Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11(8):698–704

47.

Alberg AJ, Daudt A, Huang HY, Hoffman SC, Comstock GW, Helzlsouer KJ, Strickland PT, Bell DA (2004) N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect Prev 28(3):187–193PubMedCrossRef

48.

IARC (International Agency for Research on Cancer) (1999) In: Vineis P, Malats N, Lang M, d’Errico A, Caporaso N, Cuzick J, Boffetta P (Eds), Metabolic polymorphisms and suceptibility to cancer, vol 148. Scientific Publications, Lyon, France, p 259

Titel: Active and passive smoking, IL6, ESR1, and breast cancer risk
verfasst von: Martha L. Slattery
Karen Curtin
Anna R. Giuliano
Carol Sweeney
Richard Baumgartner
Sandra Edwards
Roger K. Wolff
Kathy B. Baumgartner
Tim Byers
Publikationsdatum: 01.05.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9629-1

Springer Medizin

Active and passive smoking, IL6, ESR1, and breast cancer risk

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions

Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years

Is BRCA2 c.9079 G > A a predisposing variant for early onset breast cancer?

FBXW7 and DNA copy number instability

Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies

XRCC1 Arg399Gln and RAD51 5′UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie